A way to improve sperm quality
(57) Abstract:The invention relates to medicine, in particular to urology and andrology, and for the treatment of conditions associated with deterioration in the quality of the ejaculate. To do this, enter patient doxazosin within 4-5 weeks. The method allows to improve the semen in various pathological conditions, causing a change of spermatogenesis. The present invention relates to medicine, in particular to urology and andrology.The most important role in fertilization is the quality of the ejaculate. In various pathological processes in the male body, and, in particular, chronic prostatitis deteriorates the quality of the ejaculate, the structure and motility of the sperm.Known methods of correction of such violations as oligozoospermia, asthenozoospermia, leukospermia, and teratozoospermia, which is to assign the drugs from the group of antiestrogens, aromatase inhibitors, synthetic androgens, as well as drugs, improves microcirculation in the pelvis, and physical therapy for a period from 12 to 24 weeks.The disadvantages of the known methods are their low efficiency and lack of effect vsee time for the treatment of male infertility, my side effects: benign and malignant changes in the liver, the symptoms of hypercalcemia embolism (where injection of the drug), allergic reactions, pain at the injection site and other side effects. Many drugs require intramuscular injection, which further complicates their use for the patient. And courses, including physiotherapy. economically disadvantageous due to the need for additional equipment and personnel.One of the most common known methods of improving the quality of sperm is hormone therapy with testosterone. The drug is administered intramuscularly (there are options for subcutaneous administration, capsules, implants, and others).The disadvantages of this method are low efficiency, difficulties in the selection of individual dose, long-lasting, often more than 3-4 months with repetitive courses of therapy, additional disadvantages associated with the method of administration, possible infiltrates and abscesses at the injection site.Object of the invention is a method that improves the effectiveness of treatment, to improve the condition of patients suffering accompany the The problem is solved by the method lies in the appointment of XatralTMthe dosage of 2 mg per day for 4-5 weeks. XatralTM- doxazosin (Doxazosin) 1-(4-amino-6,7-dimethoxy-2-hintline)-4[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl] piperazine (and monoethanolamine) belongs to the group1-adrenoblokatorov. Drugs, hypotensive, vasodilator, hypolipidemic, antispasmodic.The proposed method of treatment used in the treatment of 30 patients with reductions in sperm quality, 19 of them were diagnosed with chronic prostatitis.Specific clinical examples of the implementation of the proposed method.Patient N. , 29 years appealed to the urological clinic of MMA with complaints of feeling cold in the perineum. The patient married about four years, not uses with his wife contraceptives, no children. Prostate palpation moderately painful in the right lobe, not increased, mjagkoellasticheskih consistency. Ultrasonic examination of the prostate gland with a clear straight path. Echo tissue of the prostate homogeneous, in the projection of the right lobe of the small sizes (up to 0.5 cm in diameter) genericagent Obri: echoes. Pathological entities. According to the survey: assessment of quality of life (QoL) - 3, scale of symptoms of chronic prostatitis (NIH-CPSI) - 7, international system total evaluation of diseases of the prostate (IPSS) - 5. Secret of the prostate 5-10 leukocytes in the field of view. When the analysis of semen was oligozoospermia, asthenozoospermia, the number of motile spermatozoa 31% at the rate of 50%, actively motile spermatozoa 16% at the rate of 25%, increased agglutination.The patient was scheduled therapy doxazosin 2 mg once daily for 4 weeks.At follow-up after 4 weeks the patient had no complaints. When finger rectal examination prostate painless. According to the survey: assessment of quality of life (QoL) - 2, scale of symptoms of chronic prostatitis (NIH-CPSI) and 5 international system total evaluation of diseases of the prostate (IPSS) - 4. In the analysis of a secret of a prostate, the number of leukocytes decreased to 5 in the field of view. Improved semen. The number of motile sperm was 54% at the rate of 50%, and actively-moving - 34% at the rate of 25%. All parameters of spermogram the patient is normalized. Conclusion - normosol the sperm. 9 patients improved semen quality compared to the original data. In 3 patients the effect of therapy were observed. The lack of effect in two patients of the three above, may be connected with discovered they calculous prostatitis. In the treatment of patients with deterioration in the quality of sperm was accompanied by manifestations of chronic prostatitis, 16 of them these manifestations disappeared.Thus, the method can improve sperm quality in oligospermii, asthenozoospermia and/or teratozoospermia. A way to improve sperm quality through the introduction of patient medical drug, characterized in that the quality of medication use doxazosin over 4-5 weeks.
FIELD: organic chemistry, heterocyclic compounds, medicine, pharmacy.
SUBSTANCE: invention relates to derivatives of heteroarylalkylpiperazine of the general formula (I):
wherein m = 1, 2 or 3; q means NH or oxygen atom (O); R1, R2, R3, R4 and R5 are taken independently among the group including hydrogen atom, (C1-C15)-alkyl, OR20 wherein R20 represents hydrogen atom; R6, R7 and R8 represent hydrogen atom; R9, R10, R11, R12, R13, R14, R15 and R16 are taken independently among the group including hydrogen atom, (C1-C4)-alkyl; or R9 and R10 in common with carbon atom to which they are joined form carbonyl group; R17 means heteroaryl that is taken among the group including indolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, pyridyl, benzopyrazinyl substituted optionally with 1-2 substitutes taken among the group including hydrogen atom, CF3 group, (C1-C8)-alkyl, phenyl, CON(R20)2. Compounds elicit property as a partial inhibitor of oxidation of fatty acids and can be used in therapy for protection of skeletal muscles against results of muscular or systemic diseases. Also, invention describes a pharmaceutical composition based on the claimed compounds.
EFFECT: valuable medicinal properties of compounds.
39 cl, 3 tbl, 25 ex